What We Don't Talk about When We Don't Talk about Sex: Results of a National Survey of US Obstetrician/Gynecologists

Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Journal of Sexual Medicine (Impact Factor: 3.15). 03/2012; 9(5):1285-94. DOI: 10.1111/j.1743-6109.2012.02702.x
Source: PubMed

ABSTRACT Sexuality is a key aspect of women's physical and psychological health. Research shows both patients and physicians face barriers to communication about sexuality. Given their expertise and training in addressing conditions of the female genital tract across the female life course, obstetrician/gynecologists (ob/gyns) are well positioned among all physicians to address sexuality issues with female patients. New practice guidelines for management of female sexual dysfunction and the importance of female sexual behavior and function to virtually all aspects of ob/gyn care, and to women's health more broadly, warrant up-to-date information regarding ob/gyns' sexual-history-taking routine.
To determine ob/gyns' practices of communication with patients about sexuality, and to examine the individual and practice-level correlates of such communication.
A population-based sample of 1,154 practicing U.S. ob/gyns (53% male; mean age 48 years) was surveyed regarding their practices of communication with patients about sex.
Self-reported frequency measures of ob/gyns' communication practices with patients including whether or not ob/gyns discuss patients' sexual activities, sexual orientation, satisfaction with sexual life, pleasure with sexual activity, and sexual problems or dysfunction, as well as whether or not one ever expresses disapproval of or disagreement with patients' sexual practices. Multivariable analysis was used to correlate physicians' personal and practice characteristics with these communication practices.
Survey response rate was 65.6%. Sixty-three percent of ob/gyns reported routinely assessing patients' sexual activities; 40% routinely asked about sexual problems. Fewer asked about sexual satisfaction (28.5%), sexual orientation/identity (27.7%), or pleasure with sexual activity (13.8%). A quarter of ob/gyns reported they had expressed disapproval of patients' sexual practices. Ob/gyns practicing predominately gynecology were significantly more likely than other ob/gyns to routinely ask about each of the five outcomes investigated.
The majority of U.S. ob/gyns report routinely asking patients about their sexual activities, but most other areas of patients' sexuality are not routinely discussed.

  • Source
    • "Female sexual dysfunction is prevalent in the general population, but not routinely assessed in medical care [1] [2].Manystudies,acrossa variety of disease types and patient populations, have investigated the relationship between gynecologic cancer and sexual function in women. Plausible biopsychosocial mechanisms have been proposed, mostly from observational studies, to explain the pathways through which cancer and its treatment can impair female sexual function [3, Gynecologic Oncology xxx (2015) xxx–xxx "
    [Show abstract] [Hide abstract]
    ABSTRACT: To describe patterns of response to, and assess sexual function and activity elicited by, a self-administered assessment incorporated into a new patient intake form for gynecologic oncology consultation.
    Gynecologic Oncology 01/2015; 137(1). DOI:10.1016/j.ygyno.2015.01.451 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction.  Placebo responses are substantial in many clinical trials of treatments for female sexual dysfunctions (FSDs). Recent studies from other fields suggest a need to reconceptualize placebo response and to design future trials accordingly. Aim.  The aims of this review are to (i) summarize current conceptualizations of placebo response in the literature; (ii) identify potential mechanisms of placebo response that are relevant to the study of FSD; and (iii) provide recommendations for incorporating this knowledge into design of future trials. Methods.  Narrative review of literature relevant to the topic of placebo response and FSD. Main Outcome Measures.  Possible predictors and mechanisms of placebo response in women with FSD are described based on the synthesis of empirical findings in studies of placebo. Results.  Placebo response is a complex phenomenon that represents cognitive, behavioral, motivational, and possibly relational mediating factors. Instructions given to trial participants, behavioral changes required to participate in a trial, changes in partner behavior, and interactions with study staff may influence participants' expectations of benefit and therefore their responses to placebo treatment. Side effects may enhance placebo response within active treatment arms. At present, it is unclear to what extent to which specific factors affect outcomes of clinical trials in FSD. Conclusions.  Procedural and methodological factors are likely to contribute to placebo response in trials for FSD, though additional research is needed to clarify these effects. Study designs should be reevaluated to avoid unnecessary creation or exaggeration of placebo responses and to draw appropriate conclusions from trial results. Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med **;**:**-**.
    Journal of Sexual Medicine 10/2012; 10(2). DOI:10.1111/j.1743-6109.2012.02941.x · 3.15 Impact Factor
  • Journal of Sexual Medicine 11/2012; 9(11):2733-5. DOI:10.1111/j.1743-6109.2012.02991.x · 3.15 Impact Factor
Show more


Available from